Quick Answer
Ultragenyx Pharmaceutical Inc. reported Operating Income Loss of -$535.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +0.2% in Operating Income Loss from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$6.75 million | Q2 2013: -$8.25 million | Q3 2013: -$7.76 million | Q1 2014: -$10.34 million | Q2 2014: -$13.66 million | Q3 2014: -$15.84 million | Q1 2015: -$21.50 million | Q2 2015: -$30.14 million | Q3 2015: -$39.94 million | Q1 2016: -$53.62 million | Q2 2016: -$58.05 million | Q3 2016: -$65.78 million | Q1 2017: -$69.95 million | Q2 2017: -$78.44 million | Q3 2017: -$83.71 million | Q1 2018: -$96.49 million | Q2 2018: -$94.90 million | Q3 2018: -$89.65 million | Q1 2019: -$99.21 million | Q2 2019: -$112.47 million | Q3 2019: -$118.03 million | Q1 2020: -$120.67 million | Q2 2020: -$63.06 million | Q3 2020: -$50.32 million | Q1 2021: -$106.57 million | Q2 2021: -$82.78 million | Q3 2021: -$89.83 million | Q1 2022: -$136.63 million | Q2 2022: -$141.59 million | Q3 2022: -$225.07 million | Q1 2023: -$154.11 million | Q2 2023: -$147.96 million | Q3 2023: -$145.10 million | Q1 2024: -$165.35 million | Q2 2024: -$116.36 million | Q3 2024: -$131.99 million | Q1 2025: -$142.94 million | Q2 2025: -$107.89 million | Q3 2025: -$170.89 million.
- Over the full 14 years of available data (2012 to 2025), Ultragenyx Pharmaceutical Inc.'s Operating Income Loss has declined by 3,246.9%.
- Historical annual values: Fiscal year 2025: -$535.00 million | Fiscal year 2024: -$536.00 million | Fiscal year 2023: -$569.00 million | Fiscal year 2022: -$648.92 million | Fiscal year 2021: -$381.74 million | Fiscal year 2020: -$330.12 million | Fiscal year 2019: -$424.17 million | Fiscal year 2018: -$371.37 million | Fiscal year 2017: -$328.94 million | Fiscal year 2016: -$248.01 million | Fiscal year 2015: -$147.74 million | Fiscal year 2014: -$56.78 million | Fiscal year 2013: -$32.28 million | Fiscal year 2012: -$15.99 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: